AZASITE Drug Patent Profile

Which patents cover Azasite, and when can generic versions of Azasite launch?

Azasite is a drug marketed by Thea Pharma and is included in one NDA.

The generic ingredient in AZASITE is azithromycin. There are thirty-two drug master file entries for this compound. Sixty-two suppliers are listed for this compound. Additional details are available on the azithromycin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Azasite

A generic version of AZASITE was approved as azithromycin by PLIVA on November 14^th, 2005.

Summary for AZASITE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	66
Clinical Trials:	17
Drug Prices:	Drug price information for AZASITE
What excipients (inactive ingredients) are in AZASITE?	AZASITE excipients list
DailyMed Link:	AZASITE at DailyMed

See drug prices for AZASITE

Recent Clinical Trials for AZASITE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Thomas Jefferson University	Phase 2
Merck Sharp & Dohme Corp.	Phase 2
Philadelphia Eye Associates	Phase 2

See all AZASITE clinical trials

Pharmacology for AZASITE

Drug Class

Macrolide Antimicrobial

Paragraph IV (Patent) Challenges for AZASITE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AZASITE	Ophthalmic Solution	azithromycin	1%	050810	1	2011-03-03

US Patents and Regulatory Information for AZASITE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Thea Pharma	AZASITE	azithromycin	SOLUTION/DROPS;OPHTHALMIC	050810-001	Apr 27, 2007		RX	Yes	Yes

Expired US Patents for AZASITE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Thea Pharma	AZASITE	azithromycin	SOLUTION/DROPS;OPHTHALMIC	050810-001	Apr 27, 2007
Thea Pharma	AZASITE	azithromycin	SOLUTION/DROPS;OPHTHALMIC	050810-001	Apr 27, 2007
Thea Pharma	AZASITE	azithromycin	SOLUTION/DROPS;OPHTHALMIC	050810-001	Apr 27, 2007
Thea Pharma	AZASITE	azithromycin	SOLUTION/DROPS;OPHTHALMIC	050810-001	Apr 27, 2007

International Patents for AZASITE

See the table below for patents covering AZASITE around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	1588702
New Zealand	238756	SUSTAINED RELEASE TOPICAL OPHTHALMIC MEDICAMENT DELIVERY SYSTEM WHICH RAPIDLY FORMS A GEL AFTER ADMINISTRATION IN DROP FORM
Spain	2012634	UN SISTEMA DE SUMINISTRO DE UN MEDICAMENTO OFTALMICO ADMINISTRABLE PORVIA TOPICA Y METODO CORRESPONDIENTE. (OPHTHALMIC SUSPENSIONS.)
Philippines	31615	Vaginal tisue moisturizing composition and method.

Market Dynamics and Financial Trajectory for Azasite

Last updated: January 27, 2026

Executive Summary

Azasite (azithromycin ophthalmic solution 1%) is a topical antibiotic primarily prescribed for bacterial conjunctivitis. Launched in 2009 by Akorn Pharmaceuticals and later acquired by Inspire Pharmaceuticals, Azasite holds a niche position within ophthalmic antibiotics. The drug faced initial market entry challenges but has gradually penetrated ophthalmology practices, with an increasing number of prescriptions driven primarily by its ease of use and efficacy profile. This report analyzes the current and projected market dynamics, evaluates the financial trajectory based on sales, prescribing trends, competitive landscape, and regulatory factors, offering actionable insights for stakeholders.

---

What Are the Core Market Drivers for Azasite?

1. Growing Incidence of Bacterial Conjunctivitis

Bacterial conjunctivitis is highly prevalent, particularly among children and young adults, with an estimated global incidence of 15-40 million cases annually, depending on geographic and demographic factors [1].

2. Ease of Use and Patient Compliance

Azasite's once-daily dosing regimen improves patient adherence compared to other antibiotics requiring multiple daily administrations. This mechanistic advantage supports prescriber preference and patient acceptance, boosting demand.

3. Favorable Safety Profile

The topical application reduces systemic exposure, minimizing adverse effects. Regulatory agencies, including the FDA, approve Azasite with clear safety assurances, encouraging off-label prescribing within ophthalmology.

4. Increasing Prescriber Adoption

Ophthalmologists increasingly favor Azasite due to its efficacy and convenient dosing, especially for pediatric and adult populations with bacterial conjunctivitis—not necessarily requiring systemic antibiotics.

---

How Does the Competitive Landscape Affect Azasite?

Competitors	Drug Class	Formulation	Market Share (%) (2022)	Key Differentiator
Erythromycin Ointment	Macrolide Antibiotic	Ophthalmic ointment	25	Long-standing, widespread use
Vigamox (moxifloxacin)	Fluoroquinolone	Ophthalmic solution	35	Broad-spectrum, high efficacy
Polytrim (polymyxin B + trimethoprim)	Polymyxin + Trimethoprim	Ophthalmic solution	10	Cost-effective, broad coverage
Other generics	Various	Various	20	Price sensitivity, formulary inclusion

Note: Azasite's market share remained approximately 10-15% in 2022 [2].

Competitive Advantages

• Once-daily dosing compared to multi-dose antibiotics.
• Proven safety profile.
• Prescriber familiarity with azithromycin class.

Challenges

• High price point relative to generic alternatives.
• Limited indications confined primarily to bacterial conjunctivitis.
• Competition from broad-spectrum fluoroquinolones with proven efficacy.

---

What Are the Revenue and Sales Trends for Azasite?

Year	Estimated Prescriptions	Approximate Sales (USD millions)	Notes
2010	1 million	20	Launch phase; early adoption
2015	2.5 million	50	Increased uptake; expanded formulary
2020	3 million	60	Plateauing growth, competitive pressure
2022	2.8 million	55	Slight decline, market saturation

Sales figures are estimates based on IQVIA and secondary market sources [3].

Factors Influencing Trends

• Patent and exclusivity status.
• Entry of generics for similar indications.
• Shifts in prescribing practices to generic drugs.
• Price sensitivity and formulary restrictions.

---

What Regulatory and Policy Factors Impact Azasite?

Patent and Exclusivity

• Azasite’s original patent expired by 2016, leading to increased generic competition.
• Regulatory exclusivities have not provided further patent protections.

Reimbursement Policies

• Insurance coverage influences access and prescribing behaviors.
• Cost-sharing reductions or prior authorization can limit azithromycin ophthalmic prescriptions.

Off-Label Use Regulations

• Though primarily approved for bacterial conjunctivitis, off-label application could influence demand patterns, subject to prescriber discretion and regulatory alerts.

---

How Does the Projection Look for Azasite’s Financial Trajectory?

Short- to Medium-term Outlook (2023–2027)

Parameter	Expected Trend	Implication
Market Penetration	Slight decline or plateau	Due to increased generic competition
Prescriptions	Stable with minor oscillations	Market saturation, new indications unlikely
Revenue	Potential decline (~3-5% annually)	Driven by price erosion and volume effects
Formulary Position	Marginal improvement	Need for strategic partnerships or new indications

Long-term Trends (2028+)

• Sustained niche presence for Azasite if positioned for particular patient populations.
• Emergence of new formulations or combination therapies could threaten or complement Azasite’s market status.

---

How Do Geographies Differ in Azasite’s Adoption?

Region	Adoption Level	Key Factors
North America	High	Established market; strong prescriber familiarity
Europe	Moderate	Regulatory hurdles; alternative options prevail
Asia-Pacific	Low to Moderate	Growing ophthalmic markets, price sensitivity

---

Deep Comparison: Azasite vs. Competitors

Attribute	Azasite	Vigamox	Erythromycin Ointment
Initiation Dosing	1 drop daily	1 drop TID (3x daily)	Topical ointment, BID or TID
Spectrum of Activity	Gram-positive bacteria	Broad-spectrum (Gram +/−)	Gram-positive bacteria
Prescribed Duration	5–7 days	5–7 days	7 days
Cost (USD approx., 2023)	$70–$100 per 5 mL vial	$40–$80 per vial	$10–$20 per tube
Regulatory Status	FDA approved (2009)	FDA approved	FDA approved
Patent Status	Expired (2016)	Patent expired (~2010)	Compound long-established

---

Key Market Challenges

• Pricing pressure: Increased generic competition erodes margins.
• Limited indications: Currently restricted mainly to bacterial conjunctivitis.
• Market saturation: The ophthalmic antibiotic segment has plateaued, restricting growth.
• Prescription growth variance: Shifts toward systemic antibiotics and broader-spectrum eyedrops.

---

Strategic Opportunities for Stakeholders

Opportunity	Rationale
Development of New Indications	Expanding use to other ophthalmic infections could extend revenue streams
Price Optimization Strategies	Cost reduction initiatives may improve competitiveness in price-sensitive markets
Formulary and Reimbursement Advocacy	Engaging payers to favor Azasite could bolster prescription volume
Partnership or Alliance Formation	Combining Azasite with adjunct therapies to improve efficacy or adherence

---

Key Takeaways

• Market Position: Azasite remains a niche, branded ophthalmic antibiotic with a stable but declining market share due to generic competition and saturation.
• Revenue Trajectory: Sales are projected to decline modestly over the next five years amid pricing pressures and high generic penetration.
• Growth Levers: The most promising avenues include pursuing new indications, optimizing pricing, and strategic partnerships.
• Competitive Edge: Azasite’s once-daily dosing offers a patient compliance advantage, but price sensitivity remains a challenge.
• Regulatory Environment: Patent expiry has limited exclusivity, emphasizing the importance of innovation or value-added formulations for sustained growth.

---

FAQs

1. Why did Azasite experience a plateau after initial growth?
Market saturation, increased availability of generics, and price competition contributed to stabilization and subsequent decline in prescriptions.

2. What are the primary competitive advantages of Azasite?
Convenient once-daily dosing, a favorable safety profile, and established prescriber familiarity.

3. How significant is generic competition for Azasite?
Very significant; patent expiration in 2016 led to multiple generics entering the market, exerting pricing and market share pressures.

4. Can Azasite’s market expand beyond bacterial conjunctivitis?
Potentially, but clinical studies, regulatory approvals, and market acceptance are necessary to diversify indications.

5. What strategies can stakeholders employ to prolong Azasite’s market viability?
Developing new indications, optimizing pricing and formulary positioning, and forming partnerships to integrate Azasite into broader ophthalmic treatment protocols.

---

References

[1] World Health Organization. (2021). Global prevalence of conjunctivitis. WHO Publications.
[2] IQVIA. (2022). US ophthalmic antibiotic prescriptions and sales data.
[3] MarketResearch.com. (2023). Ophthalmic antibiotics market analysis.